An Open-Label, Multicenter, Phase I/II Trial of the Safety of Escalating Doses of PRO131921 in Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Have Been Treated With a Prior Rituximab-Containing Regimen
Phase of Trial: Phase I/II
Latest Information Update: 26 Nov 2014
At a glance
- Drugs PRO 131921 (Primary)
- Indications Follicular lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions
- Sponsors Genentech
- 10 Jun 2017 Biomarkers information updated
- 30 Jun 2009 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 17 Feb 2009 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.